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1. INTRODUCTION {#irv12728-sec-0006}
===============

In Japan, the novel antiviral drug baloxavir marboxil (S‐033188) was approved in February 2018 for the treatment of influenza A and B virus infection in patients 12 years or older and in children younger than 12 years weighing 10 kg or more; it became available in March 2018. The hydrolyzed active form of baloxavir marboxil (baloxavir acid; S‐033447) inhibits the cap‐dependent endonuclease of influenza A and B viruses.[1](#irv12728-bib-0001){ref-type="ref"} In vitro studies have revealed that an I38T substitution in the polymerase acidic subunit (PA) is associated with reduced susceptibility of influenza A(H1N1)pdm09, A(H3N2), and B viruses to baloxavir.[2](#irv12728-bib-0002){ref-type="ref"}, [3](#irv12728-bib-0003){ref-type="ref"} Furthermore, in a phase II clinical trial,[3](#irv12728-bib-0003){ref-type="ref"} PA I38T and I38F substitutions emerged following exposure to baloxavir marboxil in four (3.6%) of 112 influenza A(H1N1)pdm09 viruses for which PA sequences were available. Moreover, in a phase III clinical trial, PA I38T and I38M substitutions were detected after exposure to the drug in 9.7% of 370 influenza A(H3N2) viruses.[4](#irv12728-bib-0004){ref-type="ref"} Patients infected with mutant influenza viruses carrying PA I38T or I38F exhibited prolonged viral shedding, and the median time to alleviation of symptoms was longer in baloxavir recipients infected with viruses with PA I38T or I38M substitutions than in those without substitutions.[3](#irv12728-bib-0003){ref-type="ref"}, [4](#irv12728-bib-0004){ref-type="ref"} In a pediatric study, PA I38T and I38M substitutions emerged in 18 (23.4%) of 77 influenza A(H3N2) viruses.[3](#irv12728-bib-0003){ref-type="ref"}

In Japan, two approaches have been developed to monitor the emergence of baloxavir‐resistant influenza viruses since the 2017/2018 influenza season: the focus reduction assay, which assesses baloxavir susceptibility, and sequence analysis by next‐generation sequencing (NGS), which detects amino acid substitutions at amino acid residue 38 in PA.[5](#irv12728-bib-0005){ref-type="ref"} Using NGS, in December 2018, we detected the PA I38T substitution in two clinical strains isolated from two patients 3 days after baloxavir administration.[6](#irv12728-bib-0006){ref-type="ref"} As of January 2019, PA I38T substitution was found in 11 cases infected with influenza A(H3N2) viruses, including one patient untreated with baloxavir.[7](#irv12728-bib-0007){ref-type="ref"} Although monitoring by NGS in Japan works well, this method requires skill and is labor‐intensive, and the results can take 3 days to acquire.

RNase H2‐dependent PCR (rhPCR) was recently established to enable the performance of PCR using blocked primers containing a single ribonucleotide residue that are activated by cleavage with a thermophilic archaeal RNase H2 enzyme from *Pyrococcus abyssi*.[8](#irv12728-bib-0008){ref-type="ref"} rhPCR was found to be more sensitive than standard allele‐specific PCR when applied to the detection of single‐nucleotide polymorphisms (SNPs).[8](#irv12728-bib-0008){ref-type="ref"} In this study, for the rapid and simple monitoring of influenza viruses possessing the I38T substitution in PA in a laboratory, three rhPCR‐based assays were developed for influenza A(H1N1)pdm09, A(H3N2), and B viruses, referred to as A/H1pdm PA_I38T rhPCR, A/H3 PA_I38T rhPCR, and B PA_I38T rhPCR, respectively. We evaluated these assays using cDNAs synthesized from in vitro‐transcribed RNA controls, RNAs purified from isolated viruses and clinical specimens. The assays developed in this study could be helpful for monitoring the emergence of baloxavir‐resistant influenza viruses.

2. MATERIALS AND METHODS {#irv12728-sec-0007}
========================

2.1. Primer design {#irv12728-sec-0008}
------------------

Three rhAmp SNP Assays (primer sets) for A/H1pdm PA_I38T rhPCR, A/H3 PA_I38T rhPCR, and B PA_I38T rhPCR were designed on the basis of the consensus *PA* gene sequence of A(H1N1)pdm09, A(H3N2), and B viruses isolated in the 2017/2018 influenza season using the rhAmp^®^ Genotyping Design Tool (Integrated DNA Technologies) (Table [1](#irv12728-tbl-0001){ref-type="table"}). Each rhAmp SNP Assay consisted of one gene‐specific primer and two allele‐specific primers. One allele‐specific primer was designed to detect a T at nucleotide 113 (encoding an Ile at amino acid residue 38: PA I38) and was detected with a Yakima Yellow--labeled universal probe, and the other was for detection of a C at nucleotide 113 (encoding a Thr at amino acid residue 38: PA T38) and was detected by a FAM‐labeled universal probe.

###### 

Primers for rhAmp SNP Assays

  Name                                                             Sequence (5′‐3′)                   Position[a](#irv12728-note-0003){ref-type="fn"}
  ---------------------------------------------------------------- ---------------------------------- -------------------------------------------------
  Primers for A/H1pdm PA_I38T rhPCR (Assay ID: CD.GT.BSFN7032.1)                                      
  A/H1pdm_PA rhAmp‐FY[b](#irv12728-note-0004){ref-type="fn"}       UFP1/AAACTTCCAAATGTGTGCAAArUTGCA   108‐133
  A/H1pdm_PA rhAmp‐FF[c](#irv12728-note-0005){ref-type="fn"}       UFP2/AAACTTCCAAATGTGTGCAAGrUTGCA   108‐133
  A/H1pdm_PA rhAmp‐R[d](#irv12728-note-0006){ref-type="fn"}        GCTGTGCGACAATGCTTCAATrCCAAT        12‐35
  Primers for A/H3 PA_I38T rhPCR (Assay ID: CD.GT.BGPR9916.4)                                         
  A/H3_PA rhAmp‐FY[b](#irv12728-note-0004){ref-type="fn"}          UFP1/CACCTCCAAGTGAGTGCATArUTGCT    108‐132
  A/H3_PA rhAmp‐FF[c](#irv12728-note-0005){ref-type="fn"}          UFP2/ACCTCCAAGTGAGTGCATGrUTGCT     108‐131
  A/H3_PA rhAmp‐R[d](#irv12728-note-0006){ref-type="fn"}           GCTGTGCGACAATGCTTCAACrCCGAT        12‐35
  Primers for B PA_I38T rhPCR (Assay ID: CD.GT.BGDB2770.1)                                            
  B_PA rhAmp‐FY[b](#irv12728-note-0004){ref-type="fn"}             UFP1/CCAGCAATGCTATTCAACATrCTGTG    94‐118
  B_PA rhAmp‐FF[c](#irv12728-note-0005){ref-type="fn"}             UFP2/CCAGCAATGCTATTCAACACrCTGTG    94‐118
  B_PA rhAmp‐R[d](#irv12728-note-0006){ref-type="fn"}              GCCTAATGCTGTATATGCTTTTCCTTrCTTCG   165‐193

Nucleotide positions of *PA* genes are based on cRNA sequences obtained from the GISAID database. Isolate ID numbers of A/Niigata‐C/66/2017 (A/H1pdm), A/Kanagawa/AC1731/2018 (A/H3), and B/YOKOHAMA/62/2017 are EPI_ISL_305545, EPI_ISL_311974, and EPI_ISL_286767, respectively.

Allele‐specific primer contained universal forward primer 1 (UFP1), detected by Yakima Yellow--labeled universal probe for detection of I38.

Allele‐specific primer contained universal forward primer 2 (UFP2), detected by FAM‐labeled universal probe for detection of T38.

Gene‐specific primer.
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2.2. Viruses and clinical specimens {#irv12728-sec-0009}
-----------------------------------

Influenza viruses were isolated using Madin‐Darby canine kidney (MDCK) cells, MDCK‐SIAT1 cells,[9](#irv12728-bib-0009){ref-type="ref"} AX‐4 cells,[10](#irv12728-bib-0010){ref-type="ref"} or Caco‐2 cells, and typing and subtyping of clinical isolates were performed by hemagglutination inhibition (HI) test or real‐time RT‐PCR.[11](#irv12728-bib-0011){ref-type="ref"}, [12](#irv12728-bib-0012){ref-type="ref"} All clinical strains used in this study were collected as part of the work of the National Epidemiological Surveillance of Infectious Diseases in Japan.

Nasal or pharyngeal swabs collected from suspected and contact cases of influenza suspended in virus transport medium were obtained from Eiju General Hospital, Tokyo, Japan, between September 2018 and January 2019. The study protocol was approved by the Ethics Committee at Eiju General Hospital (No. 2015‐34) and the National Institute of Infectious Diseases (No. 1016), and the study was performed in compliance with the Declaration of Helsinki.

A total of 184, 91, and 236 clinical strains of influenza A(H1N1)pdm09, A(H3N2), and B viruses, respectively, isolated in the 2017/2018 influenza season were used in this study and are listed in Tables [S1‐S3](#irv12728-sup-0001){ref-type="supplementary-material"}. Twelve clinical strains isolated in the 2018/2019 influenza season and the 11 clinical specimens used in this study are listed in Table [3](#irv12728-tbl-0003){ref-type="table"}.

2.3. RNA purification {#irv12728-sec-0010}
---------------------

RNA was purified from clinical isolates and clinical specimens using the QIAcube and QIAamp Viral RNA Mini QIAcube Kit (Qiagen) according to the manufacturer\'s protocol.

2.4. Preparation of RNA controls {#irv12728-sec-0011}
--------------------------------

*PA* genes with a T at nucleotide 113 were amplified from A/NIIGATA‐C/66/2017 (A/H1pdm), A/KANAGAWA/AC1731/2018 (A/H3), and B/YOKOHAMA/62/2017 (B) (GISAID isolate IDs: EPI_ISL_305545, EPI_ISL_311974, and EPI_ISL_286767) by RT‐PCR with the primer pairs listed in Table [S4](#irv12728-sup-0001){ref-type="supplementary-material"} using the SuperScript III One‐Step RT‐PCR System with Platinum Taq DNA Polymerase (Thermo Fisher Scientific, Waltham, MA, USA). The resulting PCR product of A/H3 was cloned using a TOPO TA Cloning Kit for Sequencing (Thermo Fisher Scientific), and those of A/H1pdm and B were cloned into the pHH21 vector.[13](#irv12728-bib-0013){ref-type="ref"} A mutation from T to C at nucleotide 113 was introduced into each gene using the primer pairs listed in Table [S4](#irv12728-sup-0001){ref-type="supplementary-material"} and the QuikChange Lightning Site‐Directed Mutagenesis Kit (Agilent Technologies). From the resulting six plasmids, *PA* genes possessing T or C at nucleotide 113 were amplified with the primer pairs listed in Table [S4](#irv12728-sup-0001){ref-type="supplementary-material"} by PCR using Phusion High‐Fidelity DNA Polymerase (New England BioLabs). From the resulting PCR products containing the T7 promoter, in vitro‐transcribed *PA* RNAs were synthesized as described previously.[14](#irv12728-bib-0014){ref-type="ref"}

2.5. Reverse transcription {#irv12728-sec-0012}
--------------------------

Reverse transcription was performed to synthesize cDNA from RNA controls and RNA purified from clinical isolates and clinical specimens with the PrimeScript™ RT Reagent Kit (Perfect Real Time) (Takara). Each 10‐µL reaction mix contained 2 µL of 5× PrimeScript buffer, 0.5 µL of PrimeScript RT Enzyme Mix, 0.5 µL of primer (2 µmol/L), 2 µL of water, and 5 µL of template RNA. cDNA was synthesized at 42°C for 15 minutes and 85°C for 5 seconds using a C1000™ Thermal Cycler (Bio‐Rad). Primers for reverse transcription of control RNAs were as follows: A_PA_F (ATGGAAGAYTTTGTGCGA) for influenza A virus RNA controls and B_PA_F (ATGGATACYTTTATTACAAGAAAC) for influenza B virus RNA controls. Primers for reverse transcription of clinical specimens and clinical isolates were as follows: Uni12 (AGCAAAAGCAGG)[15](#irv12728-bib-0015){ref-type="ref"} for influenza A viruses and Uni9 (AGCAGAAGC)[16](#irv12728-bib-0016){ref-type="ref"} for influenza B viruses.

2.6. rhPCR {#irv12728-sec-0013}
----------

rhPCR of cDNA was performed using the rhAmp^®^ SNP Genotyping System (Integrated DNA Technologies). Each 10‐µL assay contained 5 µL of rhAmp Genotyping Master Mix, 0.25 µL of rhAmp Reporter Mix, 0.5 µL of rhAmp SNP Assay (Table [1](#irv12728-tbl-0001){ref-type="table"}), 2.25 µL of water, and 2 µL of template cDNA. Cycling was performed as follows: enzyme activation for 10 minutes at 95°C, followed by 40 cycles of amplification (denaturation at 95°C for 10 seconds, annealing at 60°C for 30 seconds, and extension at 68°C for 20 seconds) using a LightCycler^®^ 480 (Roche). Fluorescent signals were collected during the extension step, and amplification data and endpoint data were analyzed using Light Cycler^®^ 480 SW1.5 software according to the manufacturer\'s instructions.

2.7. Deep sequencing {#irv12728-sec-0014}
--------------------

The *PA* gene was amplified from viral RNA using the SuperScript III One‐step RT‐PCR system with Platinum Taq (Thermo Fisher Scientific) and universal primers.[17](#irv12728-bib-0017){ref-type="ref"} A DNA library was prepared from RT‐PCR products using a QIAseq FX DNA Library Kit (Qiagen), followed by purification by Agencourt AMPure XP (Beckman Coulter). The library was sequenced with MiSeq Reagent Kits v3 and the MiSeq system (Illumina). Sequence reads were aligned to reference sequences using CLC Genomics Workbench 11 (Qiagen). A minor allele frequency threshold of 10% was used for the detection of SNPs. All sequences are available from the EpiFlu database of the Global Initiative on Sharing All Influenza Data (GISAID) (Table [3](#irv12728-tbl-0003){ref-type="table"}).

2.8. Statistical analysis {#irv12728-sec-0015}
-------------------------

Probit analysis was performed using [statplus]{.smallcaps} software (AnalystSoft Inc).

3. RESULTS {#irv12728-sec-0016}
==========

3.1. Development of rhPCR assays {#irv12728-sec-0017}
--------------------------------

Three rhPCR‐based assays, A/H1pdm PA_I38T rhPCR, A/H3 PA_I38T rhPCR, and B PA_I38T rhPCR, were developed to discriminate between influenza A(H1N1)pdm09, A(H3N2), and B viruses carrying PA I38 and PA T38, respectively (Table [1](#irv12728-tbl-0001){ref-type="table"}). These assays were developed for analysis of clinical strains and/or viruses contained in clinical specimens that had already been typed and/or subtyped using some other method.

The specificity of each assay for discriminating between viruses possessing PA I38 and PA T38 was evaluated using 1000 copies/reaction of cDNA synthesized from each RNA control in three replicates. As shown in Figure [1](#irv12728-fig-0001){ref-type="fig"}, each assay accurately discriminated between controls carrying PA I38 and PA T38.

![Endpoint fluorescence plots of A/H1pdm PA_I38T rhPCR, A/H3 PA_I38T rhPCR, and B PA_I38T rhPCR. Relative I38 (Yakima Yellow) and T38 (FAM) fluorescence intensities are plotted on the *y*‐axis and *x*‐axis, respectively. For each assay, 1000 copies/reaction of template cDNA were synthesized by reverse transcription from each RNA control. RNA controls included the PA gene segments of A/Niigata‐C/66/2017(A/H1pdm), A/Kanagawa/AC1731/2018 (A/H3), and B/YOKOHAMA/62/2017 (B) carrying I38 (blue circles) or T38 (red circles). The plot was generated using the results obtained from three replicates for each assay. Gray circles represent the results of negative controls (water)](IRV-14-436-g001){#irv12728-fig-0001}

The detection limit of each assay was determined by a Probit analysis using cDNA synthesized from serially diluted control RNAs, with six replicates for each assay (Table [2](#irv12728-tbl-0002){ref-type="table"}). The detection limits of A/H1pdm PA_I38T rhPCR for PA I38 and PA T38 were 36.8 and 34.9 copies/reaction, respectively. Those of A/H3 PA_I38T rhPCR for PA I38 and PA T38 were 29.6 and 32.5 copies/reaction, respectively, and those of B PA_I38T rhPCR for PA I38 and PA T38 were 29.3 and 33.9 copies/reaction, respectively.

###### 

Detection limits of rhPCR assays

  Template cDNA concentration[a](#irv12728-note-0008){ref-type="fn"} (copies/reaction)   No. of positive replicates/No. of tests for each assay                           
  -------------------------------------------------------------------------------------- -------------------------------------------------------- ----- ----- ----- ----- -----
  50                                                                                     6/6                                                      6/6   6/6   6/6   6/6   6/6
  25                                                                                     6/6                                                      5/6   6/6   6/6   6/6   6/6
  10                                                                                     0/6                                                      3/6   6/6   4/6   5/6   3/6
  5                                                                                      0/6                                                      1/6   3/6   0/6   3/6   0/6
  1                                                                                      0/6                                                      0/6   0/6   0/6   0/6   0/6
  0                                                                                      0/6                                                      0/6   0/6   0/6   0/6   0/6

The template cDNA for each assay was synthesized by reverse transcription from each RNA control, namely the *PA* gene segments of ^‡^A/Niigata‐C/66/2017 (A/H1pdm), ^§^A/Kanagawa/AC1731/2018 (A/H3), and ^¶^B/YOKOHAMA/62/2017 (B) carrying I38 or T38.

Concentrations of cDNA were calculated from concentrations of RNA controls with a reverse transcription rate of 100%.

John Wiley & Sons, Ltd

By using mixtures of PA I38 and PA T38 RNA controls each with a ratio of I38 to T38 of 100:0, 95:5, 90:10, 50:50, 10:90, 5:95, and 0:100, a lower percentage of limit of detection was tested for each assay. A total of 200 copies/reaction of cDNA synthesized from each mixture of RNA controls were used in four replicates. As shown in Figure [2](#irv12728-fig-0002){ref-type="fig"}, each assay was able to detect at least 5% of I38 or T38 in the mixture.

![Endpoint fluorescence plot of A/H1pdm PA_I38T rhPCR, A/H3 PA_I38T rhPCR, and B PA_I38T rhPCR. Relative I38 (Yakima Yellow) and T38 (FAM) fluorescence are plotted on the *y*‐axis and *x*‐axis, respectively. The template cDNA for each assay was synthesized by reverse transcription from a mixture of each RNA control: a ratio of I38 to T38 of 100:0 (blue circle), 95:5 (blue triangle), 90:10 (blue square), 50:50 (purple circle), 10:90 (red square), 5:95 (red triangle), and 0:100 (red circle). Two hundred copies/reaction of cDNA were used. The plot was generated using the results obtained from each assay performed in four replicates. Gray circles represent the results of the negative control (water)](IRV-14-436-g002){#irv12728-fig-0002}

3.2. Validation of rhPCR assays performed using clinical strains and clinical specimens {#irv12728-sec-0018}
---------------------------------------------------------------------------------------

Among strains isolated in the 2017/2018 influenza season, 184 influenza A(H1N1)pdm09 strains, 91 influenza A(H3N2) strains, and 236 influenza B strains (Tables [S1‐S3](#irv12728-sup-0001){ref-type="supplementary-material"}) were tested by A/H1pdm PA_I38T rhPCR, A/H3 PA_I38T rhPCR, and B PA_I38T rhPCR, respectively. All strains were determined to carry PA I38 (data not shown).

Four influenza A(H1N1)pdm09 strains isolated in the 2018/2019 influenza season and one clinical specimen positive for A(H1N1)pdm09 were tested by both A/H1pdm PA_I38T rhPCR and NGS. Similarly, eight influenza A(H3N2) strains and ten clinical specimens positive for A(H3N2) were tested by A/H3 PA_I38T rhPCR and NGS. As shown in Figure [3](#irv12728-fig-0003){ref-type="fig"} and Table [3](#irv12728-tbl-0003){ref-type="table"}, three of the influenza A(H1N1)pdm09 strains were determined to carry PA I38 by rhPCR and NGS. The remaining strain was found to carry PA T38 by rhPCR and appeared as a mixture of PA T38 and F38 according to NGS. The influenza A(H1N1)pdm09 virus derived from the clinical specimen was determined to be a mixture of PA I38 and T38 by rhPCR and NGS. Three, four, and one influenza A(H3N2) strains were determined to carry PA I38, T38, or a mixture of I38 and T38 according to rhPCR and NGS. Four, one, and five influenza A(H3N2) viruses from clinical specimens were found to carry PA I38, T38, or a mixture of I38 and T38 by rhPCR. In contrast, two, one, one, one, and five of these viruses were determined to carry PA I38; T38; M38; a mixture of I38, T38, and M38; or a mixture of I38 and T38 according to NGS.

![Endpoint fluorescence plots of A/H1pdm PA_I38T rhPCR and A/H3 PA_I38T rhPCR using cDNA synthesized from RNAs of clinical strains and clinical specimens. Relative I38 (Yakima Yellow) and T38 (FAM) fluorescence intensities are plotted on the *y*‐axis and *x*‐axis, respectively. Influenza viruses discriminated as I38, T38, or a mixture of I38 and T38 are represented as blue, red, or purple circles, respectively. Numbers in the figure indicate virus numbers listed in Table [3](#irv12728-tbl-0003){ref-type="table"}](IRV-14-436-g003){#irv12728-fig-0003}

###### 

Clinical strains and clinical specimens isolated and collected in the 2018/2019 influenza season and tested by rhPCR assays

+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| No. | Name                    | GISAID ID      | Type/subtype                | Amino acid at PA 38 |            |
+=====+=========================+================+=============================+=====================+============+
| 1   | A/KANAGAWA/88/2018      | EPI_ISL_337454 | A/H1pdm (Clinical strain)   | T                   | T: 59%     |
|     |                         |                |                             |                     |            |
|     |                         |                |                             |                     | F: 41%     |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 2   | A/YOKOHAMA/123/2018     | EPI_ISL_333604 | A/H1pdm (Clinical strain)   | I                   | I: 100%    |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 3   | A/YOKOHAMA/124/2018     | EPI_ISL_333605 | A/H1pdm (Clinical strain)   | I                   | I: 100%    |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 4   | A/YOKOHAMA/125/2018     | EPI_ISL_333606 | A/H1pdm (Clinical strain)   | I                   | I: 100%    |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 5   | A/KANAGAWA/IC1890/2019  | EPI_ISL_345217 | A/H1pdm (Clinical specimen) | Mix                 | T: 72%     |
|     |                         |                |                             |                     |            |
|     |                         |                |                             |                     | I: 28%     |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 6   | A/YOKOHAMA/133/2018     | EPI_ISL_332908 | A/H3 (Clinical strains)     | T                   | T: 100%^†^ |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 7   | A/YOKOHAMA/134/2018     | EPI_ISL_332909 | A/H3 (Clinical strain)      | I                   | I: 100%^†^ |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 8   | A/YOKOHAMA/135/2018     | EPI_ISL_332910 | A/H3 (Clinical strain)      | T                   | T: 100%^†^ |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 9   | A/YOKOHAMA/136/2018     | EPI_ISL_332911 | A/H3 (Clinical strain)      | I                   | I: 100%^†^ |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 10  | A/YOKOHAMA/56/2019      | EPI_ISL_340695 | A/H3 (Clinical strain)      | T                   | T: 100%^‡^ |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 11  | A/YOKOHAMA/60/2019      | EPI_ISL_340697 | A/H3 (Clinical strain)      | I                   | I: 100%    |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 12  | A/YOKOHAMA/61/2019      | EPI_ISL_340699 | A/H3 (Clinical strain)      | Mix                 | T: 88%     |
|     |                         |                |                             |                     |            |
|     |                         |                |                             |                     | I: 12%^‡^  |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 13  | A/MIE/41/2018           | EPI_ISL_346647 | A/H3 (Clinical strain)      | T                   | T: 100%    |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 14  | A/KANAGAWA/IC1807/2018  | EPI_ISL_340686 | A/H3 (Clinical specimen)    | I                   | I: 90%     |
|     |                         |                |                             |                     |            |
|     |                         |                |                             |                     | T: 10%^‡^  |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 15  | A/KANAGAWA/AC1817/2018  | EPI_ISL_337452 | A/H3 (Clinical specimen)    | Mix                 | T: 59%     |
|     |                         |                |                             |                     |            |
|     |                         |                |                             |                     | I: 21%     |
|     |                         |                |                             |                     |            |
|     |                         |                |                             |                     | M: 20%     |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 16  | A/KANAGAWA/IC1817/2019  | EPI_ISL_340691 | A/H3 (Clinical specimen)    | I                   | I: 100%    |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 17  | A/KANAGAWA/IC1827/2019  | EPI_ISL_337459 | A/H3 (Clinical specimen)    | Mix                 | I: 84%     |
|     |                         |                |                             |                     |            |
|     |                         |                |                             |                     | T: 16%^‡^  |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 18  | A/KANAGAWA/AC1829/2019  | EPI_ISL_337458 | A/H3 (Clinical specimen)    | Mix                 | I: 82%     |
|     |                         |                |                             |                     |            |
|     |                         |                |                             |                     | T: 18%^‡^  |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 19  | A/KANAGAWA/IC18154/2019 | EPI_ISL_345223 | A/H3 (Clinical specimen)    | I                   | I: 100%    |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 20  | A/KANAGAWA/IC1869/2019  | EPI_ISL_345211 | A/H3 (Clinical specimen)    | Mix                 | I: 84%     |
|     |                         |                |                             |                     |            |
|     |                         |                |                             |                     | T: 16%     |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 21  | A/KANAGAWA/IC1870/2019  | EPI_ISL_345212 | A/H3 (Clinical specimen)    | I                   | M: 100%    |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 22  | A/KANAGAWA/IC1894/2019  | EPI_ISL_345218 | A/H3 (Clinical specimen)    | T                   | T: 100%    |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+
| 23  | A/KANAGAWA/IC18102/2019 | EPI_ISL_345219 | A/H3 (Clinical specimen)    | Mix                 | T: 89%     |
|     |                         |                |                             |                     |            |
|     |                         |                |                             |                     | I: 11%     |
+-----+-------------------------+----------------+-----------------------------+---------------------+------------+

NGS data from references ^†^ [6](#irv12728-bib-0006){ref-type="ref"} and ^‡^ [7](#irv12728-bib-0007){ref-type="ref"}.
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4. DISCUSSION {#irv12728-sec-0019}
=============

Regardless of the type and subtype of influenza virus, all clinical strains isolated in the 2017/2018 influenza season were determined to carry PA I38 by A/H1pdm PA_I38T rhPCR, A/H3 PA_I38T rhPCR, and B PA_I38T rhPCR. These results are in agreement with previous reports that PA I38 is highly conserved among influenza A and B viruses,[3](#irv12728-bib-0003){ref-type="ref"} that the I38T substitution in PA was not detected in seasonal influenza strains isolated in the 2017/2018 influenza season in Japan,[18](#irv12728-bib-0018){ref-type="ref"} and that influenza viruses circulating in the Asia‐Pacific region between 2012 and 2018 were susceptible to baloxavir.[19](#irv12728-bib-0019){ref-type="ref"}

Five and 18 influenza A(H1N1)pdm09 and A(H3N2) clinical strains or viruses contained in clinical specimens isolated or collected in the 2018/2019 influenza season were tested by A/H1pdm PA_I38T rhPCR and A/H3 PA_I38T rhPCR, respectively. The results of the rhPCR assays for discriminating between PA I38 and PA T38 corresponded with the results of NGS except for A/KANAGAWA/IC1807/2018. According to A/H3 PA_I38T rhPCR, A/KANAGAWA/IC1807/2018 was determined to carry PA I38, whereas a mixture of PA I38 and T38 was detected by NGS. Detailed NGS analysis revealed that the percentage of PA T38 contained in the clinical specimen of A/KANAGAWA/IC1807/2018 was 10%. By using in vitro‐transcribed RNA controls, A/H3 PA_I38T rhPCR was able to detect at least 5% of T38 in the mixture, whereas it failed to detect 10% of PA T38 in A/KANAGAWA/IC1807/2018. The discrepancy between the results from RNA controls and from clinical specimens may be caused by the difference in RNA purity between in vitro‐transcribed RNA and RNA purified from a clinical specimen. Alternatively, the discrepancy between the results from the rhPCR assay and from NGS may be caused by the different the respective experimental procedures after the RNA purification step. Further evaluation with clinical specimens containing a mixture of PA I38 and T38 from future influenza seasons would be required to explain the discrepancy.

In two clinical strains, A/KANAGAWA/AC1817/2018 and A/KANAGAWA/IC1870/2019, NGS detected PA M38. A/H3 PA_I38T rhPCR was designed to discriminate between PA I38 (T at nucleotide 113) and T38 (C at nucleotide 113), not to identify M38, which is also encoded by a T at nucleotide 113; thus, rhPCR reported the amino acid as PA I38. In a clinical strain, A/KANAGAWA/88/2018, NGS detected F38. Similarly, A/H1pdm PA_I38T rhPCR was not designed to identify F38, which is encoded by a T at nucleotides 112 and 113. In this case, rhPCR only detected PA T38 in A/KANAGAWA/88/2018 and failed to detect F38.

In previous analyses involving the focus reduction assay, comparison of median IC~50~ values indicated that influenza A(H3N2) clinical strains carrying PA T38 in Japan exhibited \>100‐fold reduced susceptibilities to baloxavir compared to those of influenza A(H3N2) clinical strains carrying PA I38.[5](#irv12728-bib-0005){ref-type="ref"}, [6](#irv12728-bib-0006){ref-type="ref"}, [7](#irv12728-bib-0007){ref-type="ref"} In contrast, influenza viruses carrying the PA I38M or PA I38F substitutions exhibited only moderate reductions in susceptibility to baloxavir.[3](#irv12728-bib-0003){ref-type="ref"}, [4](#irv12728-bib-0004){ref-type="ref"}, [20](#irv12728-bib-0020){ref-type="ref"} As of July 2019, five A(H1N1)pdm09 and 30 A(H3N2) viruses in Japan had been found to carry a mutation at PA amino acid residue 38 by NGS.[18](#irv12728-bib-0018){ref-type="ref"} Of these, two A(H1N1)pdm09 viruses carried PA I38F or I38S substitutions, and two A(H3N2) viruses carried PA I38M substitution. However, the remaining A(H1N1)pdm09 and A(H3N2) viruses were found to carry PA T38 or a mixture including PA T38. It was also reported that PA T38 was the most common substitution emerging during baloxavir treatment in Japan and in the United States.[21](#irv12728-bib-0021){ref-type="ref"}, [22](#irv12728-bib-0022){ref-type="ref"}, [23](#irv12728-bib-0023){ref-type="ref"} These results suggest that our developed rhPCR assays should be able to detect the majority of PA I38 mutant viruses.

The rhPCR assays developed in this study can rapidly detect already typed and/or subtyped influenza viruses carrying the I38T substitution in PA with high sensitivity and specificity within 3‐4 hours, and can be performed on many samples at a time. Based on these results, rhPCR assays should be considered a useful tool for the screening of the PA I38T substitution and monitoring of the emergence of baloxavir‐resistant influenza viruses.
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